Leveraging Science for Lifetime Medicine

From a one-man discovery to a passionate global drug development team working on the next generation of metabolic and inflammatory therapeutics

From Bench to Bedside

We leverage science to deliver effective, safe, and tolerable lifetime medicine for inflammatory diseases based on our deep understanding of drug research and development, breakthrough mechanisms of action, and global collaborations.

Pipeline
ARMOR Phase 3 Study
Aug. 4, 2022

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

Read More
Jul. 7, 2022

Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model

Read More
Jun. 17, 2022

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

Read More